TurtleTree Labs, a Singaporean company developing cell-based milk products, has raised $30 million in the first tranche of its Series A funding round. The round was led by VERSO Capital.
TurtleTree Becomes First to Receive FDA Clearance for Precision-Fermented Lactoferrin
California-based biotech company TurtleTree has secured a “No Questions” letter from the US Food and Drug Administration (FDA) for its precision fermentation-produced lactoferrin, referred to as LF+. This correspondence indicates that the FDA has completed its review of TurtleTree’s Generally Recognized as Safe (GRAS) dossier without raising any safety concerns, allowing the ingredient to be used in food products within the United States. The FDA’s assessment of LF+ encompassed genomic, toxicological, compositional, and functional analyses, which formed part of the GRAS submission. The agency’s “No Questions” letter confirms that the agency has no further inquiries regarding the ingredient’s safety under the intended conditions of use. Fengru Lin, CEO and co-founder of TurtleTree, commented on the FDA’s decision, noting its significance for the company and the …
